Advertisement

Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects

  • Frederick G. Hayden
Chapter
Part of the Infectious Disease book series (ID)

Two classes of anti-viral agents, the M2 ion channel inhibitors (amantadine, rimantadine) and neuraminidase (NA) inhibitors (oseltamivir, zanamivir) are available for treatment and prevention of infl uenza in most countries of the world. The principle concerns about emergence of antiviral resistance in infl uenza viruses are loss of drug effi cacy, transmission of resistant variants, and possible increased virulence or transmissibility of resistant variants (1). Because seasonal infl uenza is usually an acute, self-limited illness in which viral clearance occurs rapidly due to innate and adaptive host immune responses, the emergence of drug-resistant variants would be anticipated to have modest effects on clinical recovery, except perhaps in immunocompromised or immunologically naïve hosts, such as young infants or during the appearance of a novel strain. In contrast to the limited impact of resistance emergence in the treated immunocompetent individual, the epidemiologic impact of resistance emergence and transmission could be considerable, including loss of both prophylactic and therapeutic activity for a particular drug, at the household, community, or perhaps global level. Infl uenza epidemiology in temperate climates is expected to provide some protection against widespread circulation of resistant variants, as viruses do not persist between epidemics but rather are re-introduced each season and new variants appear often (2, 3).

Keywords

Influenza Virus Avian Influenza Resistant Variant Neuraminidase Inhibitor Oseltamivir Carboxylate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hayden FG, Monto AS, Webster R, Zambon M. NISN Statement on antiviral resistance in influenza viruses. Weekly Epidemiological Record 2004; 79(33):306–308Google Scholar
  2. 2.
    Russell CA, Jones TC, Barr IG et al. The global circulation of seasonal influenza A (H3N2) viruses. science 2008; 320(5874):340–346PubMedGoogle Scholar
  3. 3.
    Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008; 453:615–619PubMedGoogle Scholar
  4. 4.
    Bright RA, Medina Mj, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. The Lancet 2005; 366:1175–1181Google Scholar
  5. 5.
    Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA: The Journal of American Medical Association-Express (online) (doi:10.1001/jama.295.8.joc60020), 295. 2-2-2006.Google Scholar
  6. 6.
    WHO/ECDC. WHO/ECDC Frequently Asked Questions for Oseltamivir Resistance. http://www.who.int/csr/disease/influenza/ oseltamivir_faqs/en/index.html. 2008.
  7. 6a.
    6a. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Current Opinion in Infectious Diseases 2008, 21:626–638PubMedGoogle Scholar
  8. 7.
    WHO Departmentof Communicable Disease Surveillance and Response. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics. 2004. http://www.who.int/csr/ resources/publications/influenza/WHO_CDS_CSR_RMD_2004_8
  9. 8.
    Hayden FG. Antiviral resistance in influenza viruses — implications for management and pandemic response. The New England Journal of Medicine 2006; 354(8):785–788PubMedGoogle Scholar
  10. 9.
    Cochran KW, Maassab HF, Tsunoda A, Berlin BS. Studies on the antiviral activity of amantadine hydrochloride. Annals of the New York Academy of Sciences 1965; 130:432–43910.PubMedGoogle Scholar
  11. 10.
    Oxford JS, Logan IS. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 1970; 226:82–83PubMedGoogle Scholar
  12. 11.
    Hay AJ. Amantadine and rimantadine — mechanisms. In: Richman DD, editor. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons Ltd, 1996:43–58Google Scholar
  13. 12.
    Hall CB, Dolin R, Gala CL et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80(2):275–282PubMedGoogle Scholar
  14. 13.
    Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. Journal of Infectious Diseases 1989; 159(3):430–435PubMedGoogle Scholar
  15. 14.
    Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. New England Journal of Medicine 1989; 321(25):1696–1702PubMedGoogle Scholar
  16. 15.
    Mast EE, Harmon MW, Gravenstein S et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134(9):988–997PubMedGoogle Scholar
  17. 16.
    Hayden FG. Amantadine and rimantadine — clinical aspects. In: Richman DD, editor. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons Ltd, 1996:59–77Google Scholar
  18. 17.
    Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-Restriction fragment length polymorphism analysis with nasopharyngeal swabs. Journal of Clinical Microbiology 2002; 40:84–88PubMedGoogle Scholar
  19. 18.
    Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. Journal of Infectious Diseases 2003; 188:57–61PubMedGoogle Scholar
  20. 19.
    Saito R, Sakai T, Sato I et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. Journal of Clinical Microbiology 2003; 41(5):2164–2165PubMedGoogle Scholar
  21. 20.
    Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. Journal of Virology 1991; 65(10):5491–5498PubMedGoogle Scholar
  22. 21.
    Tumpey TM, Garcia-Sastre A, Mikulasova A et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences of the United States of America 2002; 99(21):13849–13854PubMedGoogle Scholar
  23. 22.
    Ziegler T, Hemphill ML, Ziegler ML et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. Journal of Infectious Diseases 1999; 180(4):935–939PubMedGoogle Scholar
  24. 23.
    Dawson J. Neuraminidase inhibitor and amantadine. Lancet 2000; 355:2254PubMedGoogle Scholar
  25. 24.
    Suzuki H, Saito R, Oshitani H. Excess amantadine use and resistant viruses. Lancet 2001; 358:1910PubMedGoogle Scholar
  26. 25.
    Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Archives of Internal Medicine 1995; 155(5):533–537PubMedGoogle Scholar
  27. 26.
    Simonsen L, Viboud C, Grenfell BT et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Molecular Biology and Evolution 2007; 24(8):1811–1820PubMedGoogle Scholar
  28. 27.
    Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Research 2007; 73(2):112–117PubMedGoogle Scholar
  29. 28.
    Deyde VM, Xu X, Bright RA et al. Surveillance of Resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. The Journal of Infectious Diseases 2007; 196(2):249–257PubMedGoogle Scholar
  30. 29.
    Deyde V, Garten R, Sheu T, Gubareva L, Klimov A. Reply to Saito et al. The Journal of Infectious Diseases 2008; 197(4):632–633Google Scholar
  31. 30.
    Schmidtke M, Zell R, Bauer K et al. Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 2006; 49(5):286–293PubMedGoogle Scholar
  32. 31.
    Marozin S, Gregory V, Cameron K et al. Antigenic and genetic diversity among swine influenza A H1N1 and H1N2 viruses in Europe. Journal of General Virology 2002; 83(Pt 4):735–745PubMedGoogle Scholar
  33. 31a.
    31a. Olsen CW, Karasin AI, Carman S, Li YCW, et al. Triple reas-sortant H3N2 influenza A viruses, Canada, 2005. Emerging Infectious Diseases 2006; 12(7):1132–1135.PubMedGoogle Scholar
  34. 32.
    Gregory V, Lim W, Cameron K et al. Infection of a child in Hong Kong by an influenza A H3N2 virus closely related to viruses circulating in European pigs. Journal of General Virology 2001; 82:1397–1406PubMedGoogle Scholar
  35. 33.
    Ilyushina NA, Govorkova EA, Webster RG. Detection of amanta-dine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 2005; 341:102–106.PubMedGoogle Scholar
  36. 34.
    He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Research 2008; 77(1):72–76PubMedGoogle Scholar
  37. 34a.
    34a. Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG. Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. Journal of General Virology 2007; 88:1266–1274.PubMedGoogle Scholar
  38. 34b.
    34b. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Current Concepts: Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374–1385.Google Scholar
  39. 35.
    Hien TT, Liem NT, Dung NT et al. Avian influenza A (H5N1) in 10 patients in Vietnam. New England Journal of Medicine 2004; 350(12):1179–1188Google Scholar
  40. 36.
    Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617–619PubMedGoogle Scholar
  41. 37.
    Cheung CL, Rayner JM, Smith GJD et al. Distribution of amanta-dine-resistant H5N1 avian influenza variants in Asia. The Journal of Infectious Diseases 2006; 193(12):1626–1629PubMedGoogle Scholar
  42. 38.
    Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 2007; 73(3):228–231PubMedGoogle Scholar
  43. 39.
    Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. Journal of Infectious Diseases 1989; 159(6):1050–1056PubMedGoogle Scholar
  44. 40.
    Herlocher ML, Truscon R, Fenton R et al. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. Journal of Infect Diseases 2003; 188:1355–1361Google Scholar
  45. 41.
    Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrobial Agents & Chemotherapy 1991; 35(9):1741–1747Google Scholar
  46. 42.
    Englund JA, Champlin RE, Wyde PR et al. Common emergence of amantadine and rimantadine resistant influenza A viruses in symptomatic immunocompromised adults. Clinical Infectious Disease 1998; 26(6):1418–1424Google Scholar
  47. 43.
    Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Journal of Infectious Diseases 1995; 172(5):1352–1355PubMedGoogle Scholar
  48. 44.
    Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clinical Infectious Disease 2002; 34:e23–e25Google Scholar
  49. 45.
    Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompro-mised patient. New England Journal of Medicine 2003; 348(9):867–868PubMedGoogle Scholar
  50. 46.
    La Rosa AM, Malik S, Englund JA et al. Influenza A in hospitalized adults with leukemia and hematopoietic stem call transplant (HSCT) recipients; risk factors for progression to pneumonia. Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 25–28, 2001, 111, Abstract #418Google Scholar
  51. 47.
    Lee C, Loeb M, Phillips A et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infection Control & Hospital Epidemiology 2000; 21(11):700–704Google Scholar
  52. 53.
    Tamblyn SE. Antiviral use during influenza outbreaks in long-term care facilities. In: Osterhaus A, Cox N, Hampson A, editors. Options for the Control of Influenza I V. New York: Excerpta Medica, 2001:817–822Google Scholar
  53. 49.
    Pohani G, Henry B, Nsubuga J. Summary report of the 1999/00 Ontario influenza season. Public Health and Epidemiology Report Ontario 2000; 11(7):136–154Google Scholar
  54. 50.
    Bowles SK, Lee W, Simor AE et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. Journal of American Geriatrics Society 2002; 50:608–616Google Scholar
  55. 51.
    Drinka PJ, Haupt T. Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltami-vir treatment of symptomatic cases. Journal of the American Geriatrics Society 2007; 55(6):923–926PubMedGoogle Scholar
  56. 52.
    Hirji Z, O'Grady S, Bonham J et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing-care population. Canada Communicable Disease Report 2001; 27(3):21–24PubMedGoogle Scholar
  57. 53.
    Gravenstein SMMC, Drinka PM, Osterweil DM et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. Journal of the American Medical Directors Association 2005; 6(6):359–366PubMedGoogle Scholar
  58. 54.
    Iwahashi J, Tsuji K, Ishibashi T et al. Isolation of amantadine-resistant influenza A viruses (H3N2) from patients following administration of amantadine in Japan. Journal of Clinical Microbiology 2001; 39(4):1652–1653PubMedGoogle Scholar
  59. 55.
    Kawai N, Ikematsu H, Iwaki N, Kawamura K, Kawashima T, Kashiwagi S. A change in the effectiveness of amantadine for the treatment of influenza over the 2003–2004, 2004–2005, and 2005–2006 influenza seasons in Japan. Journal of Infection and Chemotherapy 2007; 13(5):314–319PubMedGoogle Scholar
  60. 56.
    Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Archives of Internal Medicine 1992; 152(2):390–392PubMedGoogle Scholar
  61. 57.
    Rahman M, Bright RA, Kieke BA et al. Adamantane-resistant influenza infection during the 2004–05 season. Emerging Infectious Diseases 14(1):173–6, 2008PubMedGoogle Scholar
  62. 58.
    Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. Journal of Infectious Diseases 1991; 164(5):969–972PubMedGoogle Scholar
  63. 59.
    Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. Journal of Virology 75(12):5656–62, 2001PubMedGoogle Scholar
  64. 60.
    Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrobial Agents & Chemotherapy 2005; 49(2):556–559Google Scholar
  65. 61.
    Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Research 2006; 70(3):121–131PubMedGoogle Scholar
  66. 62.
    Ison MG, Gnann JW Jr, Nagy-Agren S et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral Therapy 2003; 8:183–190PubMedGoogle Scholar
  67. 63.
    Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Current Concepts: Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 2008;358:261–73.Google Scholar
  68. 63a.
    63a. Ilyushina NA. Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza infection in mice. Antiviral Ther 2007; 12:263–370.Google Scholar
  69. 64.
    Knight V, Gilbert BE. Ribavirin aerosol treatment of influenza. [Review]. Infectious Disease Clinics of North America 1987; 1(2):441–457PubMedGoogle Scholar
  70. 65.
    Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. Journal of Infectious Diseases 1980; 141(5):548–554PubMedGoogle Scholar
  71. 66.
    Stein DS, Creticos CM, Jackson GG et al. Oral ribavirin treatment of influenza A and B. Antimicrobial Agents & Chemotherapy 1987; 31(8):1285–1287Google Scholar
  72. 67.
    Hayden FG, Sable CA, Connor JD, Lane. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antiviral Therapy 1996; 1(1):51–56PubMedGoogle Scholar
  73. 68.
    De Clercq E. Antiviral agents active against influenza A viruses. Nature Reviews: Drug Discovery 2006; 5(12):1015–1025PubMedGoogle Scholar
  74. 69.
    Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Research 2008; 78(1):91–102PubMedGoogle Scholar
  75. 69a.
    69a. Hayden F. Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 2009; 48:S3–S13.PubMedGoogle Scholar
  76. 70.
    McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors — a review. Antiviral Research 2000; 47:1–17PubMedGoogle Scholar
  77. 71.
    Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Reviews in Medical Virology 2000; 10:45–55PubMedGoogle Scholar
  78. 72.
    Zambon M, Hayden FG. Position statement: global neurami-nidase inhibitor susceptibility network. Antiviral Research 2001; 49:147–156PubMedGoogle Scholar
  79. 73.
    McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opinion on Pharmacotherapy 2002; 3(2):103–112PubMedGoogle Scholar
  80. 74.
    Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Research 2002; 54(3):143–147PubMedGoogle Scholar
  81. 75.
    Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Research 2004; 62(1):37–45PubMedGoogle Scholar
  82. 76.
    Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clinical Infectious Disease 2007; 44(2):197–202Google Scholar
  83. 77.
    Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002–2003 influenza season. Clinical Infectious Disease 2005; 40(9):1309–1316Google Scholar
  84. 78.
    Kawai N, Ikematsu H, Iwaki N et al. Zanamivir treatment is equally effective for both influenza A and influenza B. Clinical Infectious Disease 2007; 44(12):1666Google Scholar
  85. 79.
    NISN. Use of influenza antivirals during 2003–2004 and monitoring of neuraminidase inhibitor resistance. Weekly Epidemiological Record 2005; 80(17):156Google Scholar
  86. 80.
    Monto AS, Kimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrobial Agents & Chemotherapy 50(7):2395–402, 2006Google Scholar
  87. 81.
    Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. Journal of Virology 2003; 77(15):8418–8425PubMedGoogle Scholar
  88. 82.
    Hatakeyama S, Sakai-Tagawa Y, Kiso M et al. Enhanced expression of an {alpha}2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. Journal of Clinical Microbiology 2005; 43(8):4139–4146PubMedGoogle Scholar
  89. 83.
    Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrobial Agents & Chemotherapy 2005; 49(10):4075–4084Google Scholar
  90. 84.
    Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Research 2004; 103(1–2):199–203PubMedGoogle Scholar
  91. 85.
    Abed Y, Bourgault AM, Fenton RJ et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. Journal of Infectious Diseases 2002; 186(8):1074–1080PubMedGoogle Scholar
  92. 85a.
    85a. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG. Human-like receptor specificity does not affect the neurami-nidase inhibitor susceptibility of H5N1 influenza viruses. PLoS Pathogens 2008; 4(4):e1000043.PubMedGoogle Scholar
  93. 86.
    Chutinimitkul S, Suwannakarn K, Chieochansin T et al. H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. Journal of Virological Methods 2007; 139(1):44–49PubMedGoogle Scholar
  94. 86a.
    86a. Carr MJ, Sayre N, Duffy M, Connell J, Hall WW. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses. Journal of Virological Methods 2008;153:257–262.Google Scholar
  95. 87.
    Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neurami-nidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. Journal of Clinical Microbiology 2003; 41(2):742–750PubMedGoogle Scholar
  96. 88.
    Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus N1 neurami-nidase to oseltamivir carboxylate and zanamivir. Antimicrobial Agents & Chemotherapy 2002; 46(12):3809–3816Google Scholar
  97. 89.
    Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrobial Agents & Chemotherapy 2005; 49(11):4515–4520Google Scholar
  98. 90.
    Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. Journal of Infectious Diseases 1998; 178(6):1592–1596PubMedGoogle Scholar
  99. 91.
    Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrobial Agents & Chemotherapy 2001; 45(4):1216–1224Google Scholar
  100. 92.
    Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrobial Agents & Chemotherapy 2001; 45(10):2723–2732Google Scholar
  101. 93.
    Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. British Medical Journal 2003; 326(7401):1235–1239PubMedGoogle Scholar
  102. 94.
    McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial Agents & Chemotherapy 2003; 47(7):2264–2272Google Scholar
  103. 95.
    Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy 2007; 12(4 Pt B):603–616PubMedGoogle Scholar
  104. 96.
    Hurt AC, Iannello P, Jachno K et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrobial Agents & Chemotherapy 2006; 50(5):1872–1874Google Scholar
  105. 97.
    Hurt AC, McKimm-Breschkin JL, McDonald M, Barr IG, Komadina N, Hampson AW. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Research 2004; 103(1–2):205–211PubMedGoogle Scholar
  106. 98.
    Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000–2002 influenza seasons. Virus Research 2004; 103(1–2):195–197PubMedGoogle Scholar
  107. 99.
    Ferraris O, Kessler N, Valette M, Lina B. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005. Vaccine 2006; 24(44–46):6656–6659PubMedGoogle Scholar
  108. 99a.
    99a. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. Journal of Clinical Virology 2008; 41:25–28.PubMedGoogle Scholar
  109. 100.
    Hatakeyama S, Sugaya N, Ito M et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase Inhibitors. JAMA: The Journal of the American Medical Association 2007; 297(13):1435–1442Google Scholar
  110. 101.
    Lackenby A, Baldevarona J, Democratis J et al. Decreasing sensitivity of influenza B viruses. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 238, Abstract #P930Google Scholar
  111. 102.
    Neuraminindase Inhibitor Susceptibility Network. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons. Weekly Epidemiological Record 2007; 82(17):149–150Google Scholar
  112. 103.
    Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrobial Agents & Chemotherapy 2001; 45(12):3403–3408Google Scholar
  113. 104.
    Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Therapy 2006; 11(8):971–976PubMedGoogle Scholar
  114. 104a.
    104a. van der Vries E, van den Berg B, Schutten M. Fatal oseltami-vir-resistant influenza virus infection. N Engl J Med 2008; 359(10):1074–1076.PubMedGoogle Scholar
  115. 105.
  116. 105a.
    105a. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir, last quarter 2007 to first quarter 2008, Preliminary summary and future plans. 2008. http://www.who. int/csr/disease/influenza/oseltamivir_summary/en/index.html
  117. 106.
    Hurt AC, Barr IG. Novel mutations in the ‘150-cavity’ of N1 neu-raminidase confer reduced sensitivity to the neuraminidase inhibitors. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 48 Abstract #067, 2008Google Scholar
  118. 107.
    Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 73(3):228–31, 2007PubMedGoogle Scholar
  119. 108.
    Yatsyshina S, Shestopalov A, Evseyenko V et al. Isolation and molecular characterization of the influenza A/H5N1 viruses isolated during the outbreaks of avian influenza among birds in the European part of Russia in 2005: a virus strain with ozeltamivir-resistance mutation was found. Molecular Genetics, Microbiology and Virology 2008; 23(1):31–41Google Scholar
  120. 109.
    Rayner JM, Cheung CL, Smith GJD et al. Naturally occurring antiviral drug resistance in avian H5N1 virus. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 48 Abstract #068Google Scholar
  121. 109a.
    109a. Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, et al. Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol 2007 81(13):6890–6398.PubMedGoogle Scholar
  122. 110.
    Saad MD, Boynton BR, Earhart KC et al. Detection of osel-tamivir resistance mutation N2945S in humans with influenza A H5N1. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 228 Abstract # P909Google Scholar
  123. 111.
    Rameix-Welti MA, Agou F, Buchy P et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrobial Agents & Chemotherapy 2006; 50(11):3809–3815Google Scholar
  124. 112.
    Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in mice. Journal of Infectious Diseases 2005; 192(4):665–672PubMedGoogle Scholar
  125. 113.
    McKimm-Breschkin J, Selleck P, Usman TB, Johnson M. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases 2007; 13(9):1354–1357PubMedGoogle Scholar
  126. 113a.
    113a. Le MTQ, Wertheim HFL, Nguyen HD, Taylor W, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in Northern Vietnam. PLoS ONE 2008; 3(10):e3339.PubMedGoogle Scholar
  127. 114.
    Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrobial Agents & Chemotherapy 2007; 51(4):1414–1424Google Scholar
  128. 114a.
    114a. Ilyushina NA, Hay A, Yilmaz N, Boon ACM, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus Infection in mice. Antimicrobial Agents Chemother 2008; 52(11):3889–3897.Google Scholar
  129. 114b.
    114b. Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. Journal of Infectious Diseases 2008; 197:1315–1323PubMedGoogle Scholar
  130. 115.
    Thompson CI, Barclay WS, Zambon MC. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. Journal of Antimicrobial Chemotherapy 2004; 53(5):759–765PubMedGoogle Scholar
  131. 116.
    Barnett J, Cadman A, Gor D et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrobial Agents & Chemotherapy 2000; 44(1):78–87Google Scholar
  132. 117.
    Jackson HC, Roberts N, Wang Z, Belshe R. Management of influenza Use of new antivirals and resistance in perspective. Clinical Drug Investigation 2000; 20(6):447–454Google Scholar
  133. 118.
    Roberts N. Treatment of influenza with neuraminidase inhibitors: virological implications. Philosophical Transactions of the Royal Society 2001; 356(1416):1895–1897Google Scholar
  134. 119.
    Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. Journal of Infectious Diseases 2001; 183:523–531PubMedGoogle Scholar
  135. 120.
    Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437(7062):1108PubMedGoogle Scholar
  136. 121.
    Menno D. de Jong MD, Thanh TT, Khanh TH, Hien VM, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667–2672.Google Scholar
  137. 122.
    Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55(Suppl_1):i5–21PubMedGoogle Scholar
  138. 123.
    Whitley RJ, Hayden FG, Reisinger K et al. Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal 2001; 20(2):127–133PubMedGoogle Scholar
  139. 124.
    Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364(9436):759–765PubMedGoogle Scholar
  140. 125.
    Democratis J, Lakenby A, McNally T et al. A prospective study to assess the emergence and transmissibility of resistance to osel-tamivir following treatment of children with influenza. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 228, Abstract # P923Google Scholar
  141. 126.
    Gubareva LV, Matrosovich MN, Brenner MK, Bethell R, Webster RG. Evidence for zanamivir resistance in an immuno-compromised child infected with influenza B virus. Journal of Infectious Diseases 1998; 178(5):1257–1262PubMedGoogle Scholar
  142. 127.
    Ison MG, Hayden FG, Mishin V, Braciale TJ, Gubareva L. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. Journal of Infect Diseases 2006; 193:765–772Google Scholar
  143. 128.
    Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clinical Infectious Disease 2006; 43(12):1555–1561Google Scholar
  144. 129.
    Machado CM, Boas L, Mendes A et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplantation 2004; 34(2):111–114PubMedGoogle Scholar
  145. 129a.
    129a. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44:964–967.PubMedGoogle Scholar
  146. 129b.
    129b. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immuno-competent and immunocompromised murine models of influenza virus infection. Journal of Infectious Diseases 2006; 193:765–72PubMedGoogle Scholar
  147. 130.
    Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(2):113–115PubMedGoogle Scholar
  148. 131.
    Herlocher ML, Carr J, Ives J et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Research 2002; 54(2):99–111PubMedGoogle Scholar
  149. 132.
    Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. The Journal of Infectious Diseases 2004; 190(9):1627–1630PubMedGoogle Scholar
  150. 132a.
    132a. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 2008; 82(20):10052–10058.PubMedGoogle Scholar
  151. 133.
    Carr J, Ives J, Kelly L et al. Influenza virus carrying neurami-nidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectiv-ity and replicative ability in vivo. Antiviral Research 2002; 54(2):79–88PubMedGoogle Scholar
  152. 134.
    Tai CY, Escarpe PA, Sidwell RW et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrobial Agents & Chemotherapy 1998; 42(12):3234–3241Google Scholar
  153. 134a.
    134a. Rameix-Welti M-A, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathogens 2008; 4(7):e1000103PubMedGoogle Scholar
  154. 135.
    Ives JAL, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltami-vir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Research 2002; 55:307–317PubMedGoogle Scholar
  155. 136.
    Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. Journal of Virology 2007; 81(22):12418–12426PubMedGoogle Scholar
  156. 137.
    Mishin VP, Hayden FG, Signorelli KL, Gubareva LV. Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection. Antiviral Research 71(1):64–8, 2006PubMedGoogle Scholar
  157. 138.
    Gubareva LV. Characterization of influenza A and B viruses recovered from immunocompromised patients treated with antivirals. In: Kawaoka Y, editor. Options for the Control of Influenza V. Amsterdam: Elsevier BV, 2004:126–129Google Scholar
  158. 138a.
    138a. Medeiros R, Rameix-Welti AM, Lorin V, Ribaud P, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antiviral Ther 2007;12:571–576.Google Scholar
  159. 139.
    Jackson D, Barclay W, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. The Journal of Antimicrobial Chemotherapy 2005; 55(2):162–169PubMedGoogle Scholar
  160. 140.
    Calfee DP, Peng AW, Cass L, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrobial Agents & Chemotherapy 1999; 43(7):1616–1620Google Scholar
  161. 141.
    Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Research 2006; 69(1):39–45PubMedGoogle Scholar
  162. 142.
    Yun NE, Linde NS, Zacks MA et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008; 374(1):198–209PubMedGoogle Scholar
  163. 143.
    Makoto Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, and Kubo S. CS-8958, a prodrug of the new neuramini-dase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53(1):186–192PubMedGoogle Scholar
  164. 144.
    Smee DF, Bailey KW, Morrison A, Sidwell RW. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002; 48:88–93PubMedGoogle Scholar
  165. 145.
    Madren LK, Shipman C Jr, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chemistry & Chemotherapy 1995; 6(2):109–113Google Scholar
  166. 146.
    Smee D, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A(H1N1) and B viruses. Antiviral Chemistry & Chemotherapy 2006; 17(4):185–192.Google Scholar
  167. 147.
    McCaw JM, Wood RG, McCaw CT, McVernon J. Impact of emerging antiviral drug resistance on influenza containment and spread: Influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE 2008; 3(6): e2362PubMedGoogle Scholar
  168. 148.
    Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model. Journal of Infectious Diseases 1998; 177:863–873PubMedGoogle Scholar
  169. 149.
    Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 312(5772):389–391PubMedGoogle Scholar
  170. 150.
    Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Medicine/Public Library of Science 2007; 4(1):e15Google Scholar
  171. 151.
    Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy 2003; 51:977–990PubMedGoogle Scholar
  172. 152.
    Alexander ME, Bowman CS, Feng Z et al. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proceedings of the Royal Society of London — Series B: Biological Sciences 274(1619):1675–84, 2007PubMedGoogle Scholar
  173. 153.
    Handel A, Longini IM, Jr., Antia R. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Computational Biology 2007; 3(12):e240PubMedGoogle Scholar
  174. 153a.
    153a. Moghadas SM, Bowman CS, Ro G, Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE 2008: 3(3): e1839PubMedGoogle Scholar
  175. 154.
    WHO. Clinical management of human infection with avian influenza A(H5N1) virus 2007. http://www.who.int/csr/disease/avian_ influenza/guidelines/clinicalmanage07/en/index.html
  176. 155.
    Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial Agents & Chemotherapy 2002; 46(4):977–81Google Scholar
  177. 156.
    Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial Agents & Chemotherapy 2007; 51(3):845–851Google Scholar
  178. 157.
    Lu J, Guo Z, Pan X et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respiratory Research 2006; 7:43PubMedGoogle Scholar
  179. 158.
    Simmons CP, Bernasconi NL, Suguitan AL et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 2007; 4(5):e178PubMedGoogle Scholar
  180. 159.
    Hanson B, Boon A, Lim A, Webb A, Ooi E, Webby R. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respiratory Research 2006; 7(1):126PubMedGoogle Scholar
  181. 160.
    Belser JA, Lu X, Szretter K et al. DAS181, A novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. Journal of Infect Diseases 2007; 196(10):1493–1499Google Scholar
  182. 161.
    Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents & Chemotherapy 2006; 50(4):1470–1479Google Scholar
  183. 162.
    Valette M, Allard JP, Aymard M, Millet V. Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990. Antimicrobial Agents & Chemotherapy 1993; 37(10):2239–2240Google Scholar
  184. 163.
    Shih S, Lee C, Tsai H, Chen G, Tsao K. Amantadine-resistant influenza A virus in Taiwan. Journal of Formosa Medical Association 2001; 100(9):608–612Google Scholar
  185. 164.
    Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005–2006. The New England Journal of Medicine 2007; 356(3):312–313PubMedGoogle Scholar
  186. 165.
    Saito R, Suzuki Y, Li D et al. Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006–2007 influenza season in Japan. The Journal of Infectious Diseases 2008; 197(4):630–632PubMedGoogle Scholar
  187. 166.
    Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 1969; 2(629):1026–1028PubMedGoogle Scholar
  188. 167.
    Bricaire F, Hannoun C, Boissel JP. Prevention of influenza A: Effectiveness and tolerance of rimantadine hydrochloride. La Presse Medicale 1990; 19(2):69–72.PubMedGoogle Scholar
  189. 168.
    Monto AS, Pichichero ME, Blanckenberg SJ et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. Journal of Infectious Diseases 2002; 186:1582–1588PubMedGoogle Scholar
  190. 169.
    Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA: The Journal of American Medical Association 2001; 285(6):748–754Google Scholar
  191. 170.
    Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environ-ment. Bulletin of the World Health Organization 1969; 41(3):677–682PubMedGoogle Scholar
  192. 171.
    Hayden FG, Gubareva LV, Monto AS et al. Inhaled zanamivir for preventing influenza in families. New England Journal of Medicine 2000; 343(18):1282–1289PubMedGoogle Scholar
  193. 172.
    Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. Journal of Infectious Diseases 2004; 189:440–449PubMedGoogle Scholar
  194. 173.
    Hurt AC, Barr IG. Influenza viruses with reduced sensitivity to the NA inhibitor drugs in untreated young children. Community Drug Intelligence 2008; 32(1):57–62Google Scholar
  195. 174.
    Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. Journal of Clinical Virology 2008; 41:13–19PubMedGoogle Scholar
  196. 175.
    Carr J, Ives J, Tai CY et al. An oseltamivir-treatment selected influenza A/Wuhan/359/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo. Abstracts of the II International Symposium on Influenza and other Respiratory Viruses, Grand Cayman, Cayman Islands, British West Indies, December 10–12, 1999Google Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Frederick G. Hayden
    • 1
  1. 1.Department of MedicineUniversity of Virginia School of MedicineCharlottesvilleUSA

Personalised recommendations